Italy Diabetes Devices and Therapeutics Market Investment Opportunities – Analysis & Market Size by Diagnosis and Monitoring Devices, Therapeutics, Combination Drugs, Route of Administration, Type of Diabetes, Distribution Channels, End User, Competitive

According to BioIntel360, diabetes market in Italy is expected to grow by 9.3% on annual basis to reach US$3,081.4 million in 2025.

The diabetes market in the country has experienced robust growth during 2020-2024, achieving a CAGR of 10.1%. This upward trajectory is expected to continue, with the market forecast to grow at a CAGR of 7.7% during 2025-2029. By the end of 2029, the diabetes market is projected to expand from its 2024 value of USD 2,819.8 million to approximately USD 4,515.3 million.

Key Trends and Drivers in Italy
The Italian diabetes devices and therapeutics market is evolving with increased CGM usage, expanded digital health integration, growth in connected therapeutic devices, and refined regulatory policies. Over the next 2–4 years, these trends are expected to intensify, leading to improved patient monitoring, more precise treatment adjustments, and an overall enhancement in diabetes management practices.

Increase Continuous Glucose Monitoring Implementation
• Italian healthcare settings are incorporating continuous glucose monitoring (CGM) systems in both public and private clinics. Pilot projects in regions such as Lombardy and Veneto are integrating CGM data into routine diabetes management protocols.
• Revised Italian National Health Service reimbursement policies and updated clinical guidelines have supported wider CGM adoption. Recent local studies and healthcare publications highlight the benefits of real-time glucose monitoring for improved treatment planning.
• As reimbursement models evolve and clinical evidence grows, CGM adoption will likely increase. The trend is expected to intensify, leading to enhanced monitoring practices and more timely treatment adjustments.

Adopt Digital Health Platforms for Remote Monitoring
• Digital platforms for remote patient monitoring and telemedicine are increasingly deployed in diabetes care settings across Italy. Several Italian hospitals have introduced centralized data systems facilitating remote consultations and continuous monitoring.
• Government initiatives promoting digital health integration and recent policy updates drive this adoption. Broader shifts in healthcare delivery models and increased MedTech investment support the integration of digital tools into clinical practice.
• The expansion of digital health solutions is expected to continue, improving data connectivity between patients and providers. This trend will intensify, contributing to more coordinated care and efficient clinical decision-making.

Enhance Therapeutic Delivery Systems
• Connected therapeutic devices—such as smart insulin pens and automated insulin pumps—are emerging in the Italian market. Clinical evaluations in Italian healthcare facilities have focused on these systems to improve dosing accuracy and treatment adherence.
• Technological advancements and supportive findings from recent Italian studies contribute to their development. Adjustments in reimbursement policies and growing MedTech investments further facilitate their market entry.
• The adoption of connected therapeutic devices is expected to grow as clinical protocols and reimbursement frameworks adapt. Over the medium term, these systems may lead to more precise treatment regimens and improved patient management.

Refine Regulatory and Reimbursement Frameworks
• Italian regulatory bodies have updated approval processes and reimbursement policies to accommodate new diabetes devices and therapies. Recent guidelines from agencies such as AIFA reflect ongoing efforts to streamline device integration into clinical practice.
• Broader healthcare reform initiatives and cost-containment strategies have prompted these regulatory adjustments. Publications within the past 12 months emphasize the need for clear reimbursement pathways to support traditional and digital diabetes care solutions.
• Enhanced regulatory clarity will likely stimulate further investments and broader adoption of diabetes devices. The evolving reimbursement framework is expected to intensify market growth and improve access to new technologies across Italy.

Competitive Landscape in Italy
The Italian diabetes devices and therapeutics market is characterized by a dynamic mix of multinational leaders and emerging local entrants. Recent strategic partnerships, mergers, and acquisitions contribute to a more integrated market, with increased emphasis on digital connectivity and regulatory alignment. In the coming years, intensified competition and ongoing consolidation will drive further innovation and enhance patient management solutions in Italy.

Analyze Current Market Conditions
• The Italian market includes a mix of multinational corporations and local companies operating in diabetes care. A structured healthcare system with defined reimbursement routes supports market entry and product adoption.

Key Players and New Entrants
• Multinational manufacturers maintain a substantial presence in Italy through long-term relationships with public health institutions. These companies offer broad portfolios encompassing both monitoring devices and therapeutic systems.
• Local startups and technology firms are entering the market with digital health solutions tailored to Italian patient needs. Recent market analyses indicate these entrants are leveraging pilot programs and collaborations with regional hospitals to demonstrate their value.

Review Recent Partnerships, Mergers, and Acquisitions
• Recent publications report partnerships between established firms and local innovators to improve data connectivity and device interoperability. Mergers and acquisitions observed over the past 12 months indicate efforts to consolidate expertise and expand product portfolios.
• Such strategic collaborations lead to a more interconnected market landscape, with shared innovation driving regulatory compliance and product development.

Future Competitive Dynamics (2–4 Years)
• The competitive landscape is expected to evolve with increased consolidation as larger players expand their digital health capabilities. Industry analyses suggest further segmentation between traditional device providers and companies focusing on digital health innovations.
• Intensified competition is anticipated to drive product innovation and refine patient management strategies. Over the next 2–4 years, strategic partnerships and market consolidation will likely shape competitive positioning across Italy.

This report provides a detailed data-centric analysis of the diabetes industry in Italy, covering market opportunities and analysis across a range of diagnosis and monitoring devices, therapeutics, domains. With over 50+ KPIs at the country level, this report provides a comprehensive understanding of diabetes market dynamics, market size and forecast, and market share statistics.

BioIntel360’s research methodology is based on industry best practices. Its unbiased analysis leverages a proprietary analytics platform to offer a detailed view of emerging business and investment market opportunities.

Scope

This report provides an in-depth, data-centric analysis of the Italy diabetes devices and therapeutics market 2020-2029. Below is a summary of key market segments:

Diabetes Devices and Therapeutics Market Share by Category
• Diagnosis and Monitoring Devices
• Therapeutics

Diabetes Devices and Therapeutics Market Share by Diagnosis and Monitoring Devices
• Blood Glucose Monitoring Devices
• Insulin Delivery Devices
• Diabetes Management and Mobile Applications
• Artificial Pancreas Devices

Diabetes Devices and Therapeutics Market Share by Blood Glucose Monitoring Devices
• Self-Monitoring Blood Glucose Devices
• Continuous Blood Glucose Monitoring Devices
• Test Strips
• Lancets

Diabetes Devices and Therapeutics Market Share by Insulin Delivery Devices
• Insulin Pumps
• Insulin Pens
• Insulin Syringes

Diabetes Devices and Therapeutics Market Share by Therapeutics
• Oral Anti-Diabetic Drugs
• Insulin
• Non-Insulin Injectable Drugs
• Combination Drugs

Diabetes Devices and Therapeutics Market Share by Oral Anti-Diabetic Drugs
• Alpha-Glucosidase Inhibitors
• DPP-4 Inhibitors
• SGLT-2 Inhibitors

Diabetes Devices and Therapeutics Market Share by Insulin
• Basal or Long-Acting
• Bolus or Fast-Acting
• Traditional Human Insulin Drugs
• Insulin Biosimilars

Diabetes Devices and Therapeutics Market Share by Non-Insulin Injectable Drugs
• GLP-1 Receptor Agonists
• Amylin Analogue

Diabetes Devices and Therapeutics Market Share by Combination Drugs
• Combination Insulin
• Oral Combination

Diabetes Devices and Therapeutics Market Share by Route of Administration
• Subcutaneous
• Intravenous
• Others

Diabetes Devices and Therapeutics Market Share by Type of Diabetes
• Type 1 Diabetes
• Type 2 Diabetes

Diabetes Devices and Therapeutics Market Share by Distribution Channels
• Online Pharmacies
• Hospital Pharmacies
• Retail Pharmacies

Diabetes Devices and Therapeutics Market Share by End User
• Hospitals
• Diabetes Clinics
• Homecare

Reasons to Buy

• Comprehensive understanding of market structure and dynamics: Gain a detailed view of the diabetes devices and therapeutics market, including category-level segmentation (Diagnosis & Monitoring Devices and Therapeutics) and sub-segmentation by product type, route of administration, type of diabetes, distribution channel, and end user.

• Identify high-growth segments and strategic investment areas: Use segment-wise market sizing and forecasting to identify opportunities in areas such as continuous glucose monitoring, insulin delivery technologies, oral anti-diabetic drugs, and biosimilars. Tailor your market entry or expansion strategies accordingly.

• Benchmark performance across distribution and care settings: Access share analysis across online, hospital, and retail pharmacies, and evaluate usage patterns across hospitals, diabetes clinics, and homecare to support channel-specific planning and resource allocation. Show more